UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group

Diabetes Care

Abstract

To assess the efficacy over 3 years of the addition of metformin to maximum sulfonylurea therapy in type 2 diabetes. This multicenter randomized open-controlled trial was conducted in outpatient diabetes clinics in 15 U.K. hospitals. A total of 591 subjects who had already been randomly allocated to sulfonylurea therapy were taking maximum doses with suboptimal glycemic control, i.e., raised fasting plasma glucose (FPG) concentrations of 6-15 mmol/l but no significant hyperglycemic symptoms. The main outcome measures included FPG, glycated hemoglobin, protocol-defined marked hyperglycemia, body weight, blood pressure, fasting plasma lipids, compliance, and hypoglycemia and other side effects. After the addition of metformin, FPG concentrations decreased by mean (95% CI) -0.47 (-0.82 to -0.13) mmol/l over 3 years compared with an increase of 0.44 (0.07-0.81) mmol/l in subjects on sulfonylurea alone (P < 0.00001). Median FPG concentrations at 3 years were 8.6 vs. 9.9 mmol/l, respectively (P < 0.00001), and HbA1c values were 7.5 and 8.1%, respectively (P = 0.006). Adjustment for baseline BMI or FPG concentration did not affect response to therapy. Only 7% of those allocated to sulfonylurea plus metformin developed protocol-defined...Continue Reading

Citations

Sep 27, 2002·Diabetes/metabolism Research and Reviews·Guillaume Charpentier
Oct 16, 1999·Comprehensive Therapy·A A Parulkar, V A Fonseca
Jun 8, 2001·Clinical Therapeutics·J E Gerich
Feb 3, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·F GregorioP Filipponi
Mar 22, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·L M ChuangUNKNOWN Diabcare-Asia 1998 Study Group
Dec 5, 2009·Critical Reviews in Food Science and Nutrition·Emily J McAllisterDavid B Allison
Dec 16, 2010·QJM : Monthly Journal of the Association of Physicians·J R PetrieS Vella
Jul 20, 2002·International Clinical Psychopharmacology·U WernekeT A B Sanders
Jun 27, 2000·Australian and New Zealand Journal of Medicine·D Playford, G F Watts
Jul 21, 2009·Diabetes, Obesity & Metabolism·G CharpentierUNKNOWN F-PIO-100 Study Investigators
Jun 28, 2007·International Journal of Clinical Practice. Supplement·G Derosa
Jun 28, 2007·International Journal of Clinical Practice. Supplement·B Charbonnel
Jun 6, 2009·International Journal of Clinical Practice·G Schernthaner
May 12, 2009·BMC Endocrine Disorders·Sheldon W TobeRichard Z Lewanczuk
Oct 25, 2006·Cost Effectiveness and Resource Allocation : C/E·Trong K LeMaureen J Lage
May 20, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Mark C Granberry, Vivian A Fonseca
Jun 16, 2012·Indian Journal of Endocrinology and Metabolism·Vishal Gupta
Sep 10, 2014·Best Practice & Research. Clinical Gastroenterology·Emily J Dhurandhar, Scott W Keith
Jun 23, 2004·QJM : Monthly Journal of the Association of Physicians·N YounisS Farook
Jun 23, 2009·Expert Opinion on Drug Safety·Joanna Mitri, Osama Hamdy
Mar 25, 2006·Expert Opinion on Pharmacotherapy·Sherwyn L SchwartzBret Berner

❮ Previous
Next ❯

Related Concepts

Related Feeds

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.